BioRestorative Therapies's gross profit for the
three
months ended in Sep. 2024 was $0.22 Mil. BioRestorative Therapies's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $0.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioRestorative Therapies's Gross Profit
For the Biotechnology subindustry, BioRestorative Therapies's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Gross Profit distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's Gross Profit falls into.
BioRestorative Therapies Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
BioRestorative Therapies's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.35 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BioRestorative Therapies had a gross margin of 91.88% for the quarter that ended in Sep. 2024 => Durable competitive advantage
BioRestorative Therapies Gross Profit Related Terms
Thank you for viewing the detailed overview of BioRestorative Therapies's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BRTX has been successfully added to your 